Steakholder Foods Announces ADS Ratio Adjustment

Ness Ziona, Israel, July 22, 2026 (GLOBE NEWSWIRE) — Steakholder Foods Ltd. (Nasdaq: STKH), a global leader in 3D-printing technology for production of whole cuts of plant-based meat, today announced its plan to adjust the ratio of the company’s American Depositary Shares (ADSs) in relation to its ordinary shares. The adjustment will change the current ratio from one (1) ADS representing four thousand (4,000) ordinary shares to a new ratio of one (1) ADS representing twelve thousand (12,000) ordinary shares, effective on July 27, 2026. Steakholder Foods’ ADSs will continue to be traded on the Nasdaq Capital Market under the ticker “STKH,” with an updated CUSIP Number of 583435508.

Fortude among first to deliver Infor Velocity Suite agentic solutions

New York, July 22, 2026 (GLOBE NEWSWIRE) — Fortude, is now enabled to deliver the full capabilities of Infor Velocity Suite, positioning the company at the forefront of Infor partners helping CloudSuite customers diagnose inefficiencies in core business processes, then automate and optimize them. Beyond enablement, Fortude is actively expanding what’s possible on Velocity Suite, building Gen AI and agentic solutions that push the platform further.

FutureCorp Space Acquisition 1 Announces the Separate Trading of its Class A Ordinary Shares and Warrants Commencing July 27, 2026

 New York, NY, July 22, 2026 (GLOBE NEWSWIRE) — FutureCorp Space Acquisition 1 (NYSE: FTRAU) (the “Company”) announced today that holders of the Company’s units may elect to separately trade the Class A ordinary shares and warrants underlying such units commencing on July 27, 2026. Each unit consists of one Class A ordinary share and one half of one redeemable warrant of the Company. No fractional warrants will be issued upon separation of the units and only whole warrants will trade.

Serina Therapeutics Appoints Farrell Simon to its Board of Directors

HUNTSVILLE, Ala., July 22, 2026 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company advancing its proprietary POZ Platform drug optimization technology, today announced the appointment of Farrell Simon, Pharm. D., to its Board of Directors, effective immediately. Dr. Simon will also serve on the Board’s Audit and Compensation Committees.